Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
November 2016, Vol 7, No 10
November 2016, Vol 7, No 10
Certain Measures Can Lower the High Cost of USP 800 Compliance
By
Meg Barbor, MPH
USP 800 Compliance
November 2016, Vol 7, No 10
Chicago, IL—Maintaining a clean room compliant with US Pharmacopeial Convention Chapter 800 (USP 800) can come with a significant price tag, but noncompliance can drive up costs to oncology practices and institutions. However, certain measures can contribute to the successful construction, renovation, and maintenance of hazardous drug sterile compounding spaces in an oncology setting, according to Ryan A. Forrey, PharmD, MS, FASHP, Director of Pharmacy, Emory University Hospital Midtown, Atlanta, GA. Dr Forrey provided practical tips related to USP 800 compliance in clinical practice at the 2016 Annual Hematology/Oncology Pharmacy Association (HOPA) Oncology Pharmacy Practice Management Program.
Read Article
Sustol First Extended-Release 5-HT3 Receptor Antagonist Approved for the Prevention of Acute and Delayed CINV
By
Lisa A. Raedler, PhD, RPh
Drug Updates
November 2016, Vol 7, No 10
Of the potential side effects of chemotherapy, nausea and vomiting remain among the most fear-inducing events. If appropriate prophylaxis were not provided, more than 70% of patients with cancer who receive chemotherapy would have nausea and/or vomiting.
Read Article
SGX942 Decreases Duration of Severe Oral Mucositis in Patients with Head and Neck Cancer
By
Meg Barbor, MPH
Symptom Management
November 2016, Vol 7, No 10
Adelaide, Australia—SGX942, a novel agent that is first in its class, decreased the incidence of severe oral mucositis in patients with head and neck cancer undergoing chemoradiation, according to new research led by Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer, Soligenix, Princeton, NJ, and Mahesh R. Kudrimoti, MD, Professor of Radiation Medicine, University of Kentucky, Lexington.
Read Article
Managing Delirium in Patients with Cancer
By
Meg Barbor, MPH
Symptom Management
November 2016, Vol 7, No 10
Delirium is an exceedingly prevalent syndrome among patients with cancer, but is underrecognized and undertreated, according to Alan Valentine, MD, Chair, Department of Psychiatry, The University of Texas M.D. Anderson Cancer Center, Houston, and Darryl Etter, PsyD, Clinical Psychologist, VA Eastern Colorado Health Care System, Denver, at a webinar hosted by the American Psychosocial Oncology Society in July 2016.
Read Article
Trajectory of Illness and Distress in Patients Undergoing Stem-Cell Transplantation
By
Chase Doyle
Palliative Care
,
Personalized Medicine
November 2016, Vol 7, No 10
San Francisco, CA—As a result of recent advances in therapy, indications for stem-cell transplant are expanding, along with the number of patients eligible for the procedure. However, the intense and cure-oriented nature of transplants can lead to various forms of distress in patients who undergo this treatment, said Christina K. Ullrich, MD, MPH, Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, at the 2016 Palliative Care in Oncology Symposium.
Read Article
Disparities in Rehospitalization Rates Among Patients with Advanced Cancer
By
Chase Doyle
Palliative Care
,
Personalized Medicine
November 2016, Vol 7, No 10
San Francisco, CA—In addition to being costly for public and private payers, hospital readmissions can lead to increased risk for complications, hospital-acquired infections, and psychological distress in patients with advanced cancer. Although preventing readmissions would improve patient outcomes and decrease healthcare costs, the underlying causes of rehospitalization are not completely understood, suggested Robin L. Whitney, RN, PhD, Betty Irene Moore School of Nursing, University of California, Davis, and colleagues in a poster presentation at the 2016 Palliative Care in Oncology Symposium.
Read Article
NCCN Unveils New Clinical Guidelines for Myelofibrosis
By
Nick Bryant
NCCN Hematologic Cancers Highlights
November 2016, Vol 7, No 10
New York, NY—Myeloproliferative neoplasms (MPNs) include myelofibrosis, polycythemia vera, and essential thrombocytopenia, and affect an estimated 295,00 individuals in the United States. MPNs represent a diverse array of diseases. This has led to the generation of various treatment guidelines that are often contradictory and difficult to interpret. However, the National Comprehensive Cancer Network (NCCN) is developing a unified field theory on the diagnosis and treatment of MPNs.
Read Article
Shifting Treatment Paradigms for Multiple Myeloma
By
Nick Bryant
NCCN Hematologic Cancers Highlights
November 2016, Vol 7, No 10
New York, NY—How to integrate the many new drugs recently approved for multiple myeloma into clinical practice was a topic addressed by Carol Ann Huff, MD, Director of the Myeloma Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies.
Read Article
Rethinking Radiotherapy for Early-Stage Hodgkin Lymphoma
By
Nick Bryant
NCCN Hematologic Cancers Highlights
November 2016, Vol 7, No 10
New York, NY—In a presentation at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies, Ranjana H. Advani, MD, Saul Rosenberg Professor of Lymphoma, Stanford University Medical Center, CA, and Vice Chair of the NCCN’s non-Hodgkin and Hodgkin lymphoma guidelines panel questioned the necessity of using radiotherapy in patients with stage I or stage II Hodgkin lymphoma.
Read Article
Are We Making Progress in Acute Myeloid Leukemia?
By
Nick Bryant
Leukemia
,
NCCN Hematologic Cancers Highlights
November 2016, Vol 7, No 10
New York, NY—Acute myeloid leukemia (AML) was a hot topic at the 2016 National Comprehensive Cancer Network (NCCN) Congress on Hematologic Malignancies. Jessica K. Altman, MD, Associate Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, assured attendees that time was not standing still for patients with AML.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma